Projects per year
Search results
-
Active
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Perkins, A. (Primary Chief Investigator (PCI))
6/11/24 → 5/11/26
Project: Research
-
Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management
Mithraprabhu, S. (Primary Chief Investigator (PCI)), Khong, T. (Chief Investigator (CI)), Reynolds, J. (Chief Investigator (CI)), Murray, D. (Chief Investigator (CI)), Shah, J. (Chief Investigator (CI)), Wellard, C. (Chief Investigator (CI)), Spencer, A. (Associate Investigator (AI)), Ross, J. (Associate Investigator (AI)), Perkins, A. (Associate Investigator (AI)), Marks, A. (Associate Investigator (AI)), Beer, H. (Associate Investigator (AI)) & Henderson, M. (Associate Investigator (AI))
1/04/24 → 31/12/26
Project: Research
-
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Perkins, A. (Primary Chief Investigator (PCI))
12/09/23 → 12/09/26
Project: Research
-
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
Perkins, A. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
13/07/23 → 12/07/25
Project: Research
-
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG300) in Patients with Polycythemia Vera
Perkins, A. (Primary Chief Investigator (PCI)) & Malherbe, M. (Project Manager)
18/10/22 → 31/10/25
Project: Research
-
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/ul).
Perkins, A. (Primary Chief Investigator (PCI)), Ma, C. K. K. (Chief Investigator (CI)) & Kennedy, N. (Project Manager)
16/03/21 → 31/12/26
Project: Research
-
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Perkins, A. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
4/03/21 → 31/12/26
Project: Research
-
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1).
Perkins, A. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
12/10/20 → 31/12/25
Project: Research
-
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2).
Perkins, A. (Primary Chief Investigator (PCI)), Kennedy, N. (Project Manager), Chuah, H. (Chief Investigator (CI)), Arbelaez, A. (Chief Investigator (CI)) & Prasad, R. (Chief Investigator (CI))
12/10/20 → 31/12/25
Project: Research
-
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis
Perkins, A. (Primary Chief Investigator (PCI))
6/03/20 → 31/12/25
Project: Research
-
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
Perkins, A. (Primary Chief Investigator (PCI)), Leahy, M. F. (Chief Investigator (CI)), Ross, D. M. (Chief Investigator (CI)), Prasad, R. (Chief Investigator (CI)), Kennedy, N. (Project Manager) & Choi, P. (Chief Investigator (CI))
5/02/20 → 31/12/25
Project: Research
-
A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera (KRT-232-102)
Perkins, A. (Primary Chief Investigator (PCI)), Burbury, K. L. (Chief Investigator (CI)) & Kennedy, N. (Project Manager)
20/01/20 → 31/12/25
Project: Research
-
An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor (KRT-232-101)
Perkins, A. (Primary Chief Investigator (PCI)), Ross, D. M. (Chief Investigator (CI)), Kennedy, N. (Project Manager), Yeh, P. (Partner Investigator (PI)) & Wright, M. (Chief Investigator (CI))
20/01/20 → 31/12/25
Project: Research
-
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of Fedratinib compared to best available therapy in subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and previously treated with ruxolitinib (The FREEDOM 2 trial)
Perkins, A. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
Bristol-Myers Squibb (Australia)
16/12/19 → 31/12/25
Project: Research
-
Finished
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (POST-PV/ET MF)
Perkins, A. (Primary Chief Investigator (PCI)), Ross, D. M. (Chief Investigator (CI)) & Kennedy, N. (Project Manager)
5/05/21 → 31/12/24
Project: Research
-
Gene editing to cure sickle cell disease
Perkins, A. (Primary Chief Investigator (PCI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/21 → 31/12/24
Project: Research
-
Validation of new druggable JAK-STAT targets in myeloproliferative neoplasms
Perkins, A. (Primary Chief Investigator (PCI))
1/01/20 → 31/12/22
Project: Research
-
Development of Improved Biomarkers and Targeted Therapies for Myeloproliferative Neoplasms
Perkins, A. & Butler, L.
1/01/20 → 27/10/22
Project: Research
-
A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients.
Perkins, A. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
23/08/19 → 31/12/24
Project: Research
-
Improving survival in myelofibrosis
Perkins, A. (Primary Chief Investigator (PCI)), Ross, D. M. (Chief Investigator (CI)), Lane, S. W. (Chief Investigator (CI)), Forsyth, C. J. (Chief Investigator (CI)), Wei, A. (Chief Investigator (CI)), Curtis, D. (Chief Investigator (CI)), Shortt, J. (Chief Investigator (CI)), Erber, W. N. (Chief Investigator (CI)) & Stevenson, W. S. (Chief Investigator (CI))
Department of Health and Aged Care (Australia)
3/01/19 → 31/12/23
Project: Research
-
From genomics to new treatments for myeloproliferative neoplasms
Gillinder, K. (Primary Chief Investigator (PCI)) & Perkins, A. (Chief Investigator (CI))
Myeloproliferative Neoplasm (MPN) Australia Limited (trading as Ruby Red Foundation)
1/08/18 → 31/07/19
Project: Research
-
-
-
Kruppel-like factors and the methylome
Perkins, A. (Primary Chief Investigator (PCI)), Lister, R. (Chief Investigator (CI)) & Dinger, M. E. (Partner Investigator (PI))
30/09/17 → 29/09/20
Project: Research
-
Trans-acting factors in fetal hemoglobin silencing
Perkins, A. (Primary Chief Investigator (PCI)), Crossley, M. (Chief Investigator (CI)) & Mackay, J. (Chief Investigator (CI))
NIH - National Institutes of Health (United States of America)
15/04/03 → 31/12/03
Project: Research
-
Denaturing high pressure liquid chromatography (DHPLC) system
O'Bryan, M. (Primary Chief Investigator (PCI)), Clyne, C. (Chief Investigator (CI)), Cram, D. (Chief Investigator (CI)), Elefanty, A. (Chief Investigator (CI)), Fuller, P. J. (Chief Investigator (CI)), Harley, V. (Chief Investigator (CI)), McLachlan, R. (Chief Investigator (CI)), Perkins, A. (Chief Investigator (CI)), Simpson, E. (Chief Investigator (CI)), Stanley, E. (Chief Investigator (CI)) & de Kretser, D. (Chief Investigator (CI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/03 → 31/12/03
Project: Research
-
Towards renal regeneration: Isolation, characterization, and functional analysis of renal stem cells
Bertram, J. (Primary Chief Investigator (PCI)), Anderson, W. (Chief Investigator (CI)), Caruana, G. (Chief Investigator (CI)), Pera, M. (Chief Investigator (CI)) & Perkins, A. (Chief Investigator (CI))
NIH - National Institutes of Health (United States of America)
30/09/02 → 30/09/05
Project: Research
-
Growing haematopoeitic stem cells for ES cells
Perkins, A. & Pera, M.
1/01/02 → 31/12/02
Project: Research
-
Microisolators, Laminar Flow Hoods and Microinjection Suite to Equip the Specific Pathogen Free Genetically Modified Mouse Facility At Monsh University
Summers, R. (Primary Chief Investigator (PCI)), Bertram, J. (Chief Investigator (CI)), Lawrence, A. (Chief Investigator (CI)), Mercer, J. (Chief Investigator (CI)) & Perkins, A. (Chief Investigator (CI))
1/01/00 → 31/12/02
Project: Research